Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Scinai Immunotherapeutics Ltd./ 6-K

SEC Filing · 6-K

Scinai Immunotherapeutics Ltd.

SEC Filing

Filed Aug 26, 2026Accepted Aug 26, 2026, 8:13 AM EDTCIK 1611747Accession 0001213900-26-093738
View company →Permanent SEC source ↗
Share

Company context

We are a biopharmaceutical company focused on the development of innovative immunology therapies and the operation of a contract development and manufacturing organization. We are advancing a pipeline of therapeutic candidates licensed from the Max Planck Society. We also own Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

Current securities

SCNINASDAQ · ADR · Current
Historical securities (1)
BVXVWNASDAQ · WARRANT · Historical · closed May 14, 2020

Recent company filings

  1. F-1 filingSep 24, 2026
  2. 6-K filingSep 21, 2026
  3. 6-K filingSep 8, 2026
  4. EFFECT filingAug 28, 2026
  5. POS AM filingAug 27, 2026

As-filed source

Primary evidence
As filedOpen full document ↗